AngelExchange-Logo-posBoundary Capital Partners has announced it is raising a £10m fund to invest further into British technology and life science businesses. It will be the fourth in the successful line of Boundary Capital funds.

The AngelPlus fund is an evergreen fund designed to give investors access to a portfolio of early stage technology and life science companies. Participants will invest alongside the experienced investment team at Boundary Capital and benefit from their unique ‘Venturer’ model, where experienced operators choose to directly support the management teams Boundary Capital invests in, whilst also directly investing into those businesses.

Investors will have access to private advisory reports on the latest opportunities, receive co-investment rights, as well as benefiting from the EIS/SEIS tax incentives. Furthermore, Boundary Capital has enhanced is Deal flow capability through being the founder member and only fund of AngelExchange, the sole private clearing house of leading angel clubs, crowdfunders and early stage incubators.

The AngelPlus Fund follows on from Boundary Capital’s previous three funds, which includes success stories like Desktop Genetics who has raised over $2m from leading international growth investors and CertiVox, a disruptive security software business that raised $8m of Series B strategic investment.

Dan Somers, Managing Partner at Boundary Capital adds: “It’s exciting times at Boundary Capital, we have strengthened our team, helped form the AngelExchange and have now launched the AngelPlus Fund. We want to change the way early stage venture investing is done and we have put the structures in place to achieve it.”

Write a comment:


Your email address will not be published.

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA